couter

ANABAnaptysbio, Inc.

Anaptysbio, Inc. (ANAB) is a royalty-focused biopharma company that earns revenue through licensing agreements with pharmaceutical firms, primarily for its T-cell engager therapies, including Jemperli and imsidolimab. The next catalyst is Jan 24, 2027 — Q3 2026 Earnings Release, which will test the company’s ability to deliver on its royalty model and provide clarity on its partnership progress.

  • ANAB has a narrow revenue base, relying heavily on a few key collaborations, with Jemperli and imsidolimab as its primary sources of income.
  • The company has a high net loss margin, with TTM net income of -$115.03M and free cash flow of -$166.07M, reflecting the capital intensity of its royalty model.
  • Revenue growth has been explosive, up 157% YoY, but profitability remains elusive, with a TTM net margin of -75.7%.

The Read

2% after Q1 2026 earnings met expectations without upside surprise.
Nov 10, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Tue10Nov

    The release will test the company's ability to maintain momentum post-spin, with a focus on revenue growth and cost optimization. This differs from the last print where the focus was on cost management and margin compression.

  • Tue9Feb

    The release will test the company's ability to deliver on the post-spin guidance, with a focus on revenue growth and royalty updates. This differs from the last print where the focus was on cost management and margin compression.

  • Mon10May

    The release will test the company's ability to maintain momentum post-spin, with a focus on revenue growth and cost optimization. This differs from the last print where the focus was on cost management and margin compression.

  • Mon2Aug

Past

  • Mon3Aug

    Actual outcome: Bull · $54.99 at outcome

    AnaptysBio reported Q2 2026 EPS of -$1.84, meeting consensus estimates exactly. The stock exceeded the bull target as investors reacted positively to the company's successful transition into a focused royalty management company post-spin, which eliminated prior R&D burn and established a 95% targeted EBIT margin with over $140 million in net cash. Optimism surrounding escalating Jemperli royalties from GSK further drove the bullish price action.

    First earnings print following recent spin-off activities, requiring updated full-year forward guidance and cash runway estimates.

  • Tue12May

    Actual outcome: Bear · $63.21 at outcome

    AnaptysBio reported an EPS actual of -1.84, matching the estimate, but the stock fell 3.5% due to mixed guidance and uncertainty around partnership progress. The earnings beat was overshadowed by concerns over the company's ability to meet long-term revenue targets, leading to a bearish price reaction.

  • Tue3Mar

    Actual outcome: Bear · $39.80 at outcome

    AnaptysBio reported Q4 2025 EPS of $1.79, exactly meeting consensus estimates, alongside updates on the GSK Jemperli milestone accrual. While the in-line earnings and milestone visibility drove a 13% relief rally, the stock's closing price of $39.80 failed to reclaim the $44.00 bear floor, resulting in a bear classification.